

Zzoma® Surpasses 2,000 Prescribing Physicians, Covering 25% of U.S. Sleep Specialists and Nearly 60% of VA Locations

BALA CYNWYD, PA, UNITED STATES,
September 15, 2025 /

EINPresswire.com/ -- Sleep Specialist, LLC (DBA 2Z Medical) today announced that more than 2,000 board-certified sleep medicine physicians across the United States have now prescribed Zzoma® for patients with positional obstructive sleep apnea (POSA). This milestone corresponds to over 25% of all U.S. sleep medicine specialists, underscoring Zzoma's widespread

adoption as a clinically proven and patient-friendly alternative to CPAP. Zzoma® has also been prescribed in practices across all 50 states, demonstrating its broad national impact.



Zzoma® is an FDA-cleared positional therapy device designed to treat mild to moderate positional OSA by gently preventing patients from sleeping on their backs. Clinical studies have shown that Zzoma® achieves therapeutic outcomes equivalent to CPAP in patients with mild to moderate positional OSA. These advantages have made Zzoma® an increasingly popular option among healthcare providers.

"This milestone reflects the growing confidence physicians have in Zzoma® as a clinically proven alternative to CPAP," - [REDACTED], [REDACTED], [REDACTED]. "The adoption by over 2,000 physicians underscores our commitment to value-based care by providing a therapy that is clinically equivalent to CPAP, expands patient access, and significantly lowers costs for payers. [\[REDACTED\]](#)

"In my practice, a significant number of patients with positional OSA struggle to adhere to CPAP therapy long-term," - [REDACTED], [REDACTED], a sleep physician at the Sleep Therapy & Research Center in San Antonio Texas. "Zzoma® offers an effective, non-invasive alternative that is easy for patients to adopt. Having a clinically proven option like Zzoma® allows me to personalize treatment and significantly improves my ability to get patients the therapeutic outcomes they need."

In addition, Zzoma® has already been prescribed in more than 100 out of 170 VA medical facilities nationwide, representing access in nearly 60% of the U.S. Department of Veterans Affairs healthcare system—a major step forward in delivering accessible care to veteran patients.

With ongoing patient adherence challenges to CPAP therapy and increasing demand for alternative CPAP therapy options, Zzoma® continues to deliver clinically validated outcomes, insurer coverage (including Blue Cross Blue Shield plans), and enhanced access to effective sleep apnea treatment nationwide.

For more information about Zzoma® and its clinical evidence, visit www.zzomaosa.com.

ZZ Medical is the developer and manufacturer of Zzoma®, an FDA-cleared positional therapy

device for obstructive sleep apnea. With a focus on clinically validated, cost-effective, and patient-friendly solutions, the company partners with leading providers and payers to expand access to sleep health innovation.

ZZ Medical is the developer and manufacturer of Zzoma®, an FDA-cleared positional therapy

Sleep Specialist, LLC

Info@zzomaosa.com

www.zzomaosa.com

+1 877-799-9662

ZZOMA

Sleep Specialist, LLC

+1 877-799-9662

info@zzomaosa.com

This press release can be viewed online at: <https://www.einpresswire.com/article/847761352>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.